Business
Endonovo Therapeutics Announces Complimentary New Product
Endonovo Therapeutics Announces Complimentary New Product.
About this update from Endonovo Therapeutics, Inc.
[{"type":"text","content":"\nLOS ANGELES, CA, Nov. 08, 2018 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc. (OTCQB: ENDV) (\"Endonovo\" or the \"Company\"), a commercial-stage developer of non-invasive Electroceutical™ therapies, today announced the expansion of their suite of complimentary products with the ORTHOHALO™.\n ORTHOHALO™ is an easy-to-use, non-invasive device delivering targeted Pulsed ElectroMagnetic Field (tPEMF) therapies to reduce pain and enhance post-surgical recovery, naturally. Its patented non-pharmacologic process uses proprietary technology to reduce pain, swelling, and inflammation. There are no known side effects and no potential for overdose or dependency. Alan Collier, CEO of Endonovo Therapeutics, stated, “My team and I have been working diligently identifying opportunities to leverage our technologies while addressing the needs of current and potential customers in our ongoing efforts to provide patients Opioid alternatives. ORTHOHALO™ allows us to strengthen our industry reach and further revenue generation. In addition, this allows us the opportunity to have broader discussions during each customer visit, providing more comprehensive solutions and further establishing our credibility and ability to address each unique market.” About ORTHOHALO™ ORTHOHALO™ is a new product line designed to provide personalized treatments for orthopedic, sports, and on the job injuries. ORTHOHALO™ aims to accomplish this by providing each patient a customized application that can be used in conjunction with a wide range of bracing, splint, and other products. ORTHOHALO™ is the only PEMF device that can be used to provide around-the-clock pain management and edema control for orthopedic patients. About Endonovo Therapeutics Endonovo Therapeutics, Inc. is a commercial-stage developer of non-invasive wearable Electroceuticals™ Therapies. The Company's current portfolio of commercial and clinical-stage wearable Electroceuticals™ Therapies addresses wound healing, pain, post-surgical pain and edema, cardiovascular disease, chronic kidney disease, and Central Nervous System (CNS) Disorders, including traumatic brain injury (TBI), acute concussions, post-concussion syndrome and multiple sclerosis. The Company's non-invasive Electroceutical™ System device, SofPulse&...